Filing Details
- Accession Number:
- 0001209191-22-059883
- Form Type:
- 4
- Zero Holdings:
- No
- Publication Time:
- 2022-12-05 19:52:37
- Reporting Period:
- 2022-12-01
- Accepted Time:
- 2022-12-05 19:52:37
- SEC Url:
- Form 4 Filing
Issuer
| Cik | Name | Symbol | Sector (SIC) | IRS No |
|---|---|---|---|---|
| 1750019 | Tcr2 Therapeutics Inc. | TCRR | Biological Products, (No Disgnostic Substances) (2836) | 474152751 |
Insiders
| Cik | Name | Reported Address | Insider Title | Director | Officer | Large Shareholder | Other |
|---|---|---|---|---|---|---|---|
| 1760104 | Quintas Alfonso Cardama | C/O Tcr2 Therapeutics 100 Binney Street Cambridge MA 02142 | Chief Medical Officer | No | Yes | No | No |
Reported Non-Derivative Transactions
| Sec. Name | Acquisiton - Disposition | Date | Amount | Price | Remaning Holdings | Equity Swap Involved | Form Type | Code | Nature of Ownership | Explanation |
|---|---|---|---|---|---|---|---|---|---|---|
| Common Stock | Acquisiton | 2022-12-01 | 95,385 | $0.00 | 142,300 | No | 4 | M | Direct | |
| Common Stock | Disposition | 2022-12-02 | 3,636 | $1.39 | 138,664 | No | 4 | S | Direct |
| Equity Swap Involved | Form Type | Code | Nature of Ownership | Explanation |
|---|---|---|---|---|
| No | 4 | M | Direct | |
| No | 4 | S | Direct |
Reported Derivative Transactions
| Sec. Name | Sec. Type | Acquisiton - Disposition | Date | Amount | Price | Amount - 2 | Price - 2 |
|---|---|---|---|---|---|---|---|
| Common Stock | Restricted Stock Unit | Acquisiton | 2022-12-01 | 69,025 | $0.00 | 69,025 | $0.00 |
| Common Stock | Restricted Stock Unit | Acquisiton | 2022-12-01 | 17,545 | $0.00 | 17,545 | $0.00 |
| Common Stock | Restricted Stock Unit | Acquisiton | 2022-12-01 | 8,815 | $0.00 | 8,815 | $0.00 |
| Remaning Holdings | Exercise Date | Expiration Date | Equity Swap Involved | Transaction Form Type | Transaction Code | Nature of Ownership |
|---|---|---|---|---|---|---|
| 1,409 | No | 4 | M | Direct | ||
| 6,489 | No | 4 | M | Direct | ||
| 9,549 | No | 4 | M | Direct |
Reported Non-Derivative Holdings
| Sec. Name | Remaning Holdings | Nature of Ownership | Explanation |
|---|---|---|---|
| Common Stock | 46,915 | Direct |
Footnotes
- Represents the the aggregate number of common stock converted from restricted stock units granted to the reporting person on 11/17/2022pursuant to the issuer's offer to exchange eligible options for new restricted stock units program.
- Each restricted stock unit represents a right to receive one share of the issuer's common stock at the time of vesting for no consideration.
- The sales reported represent the number of shares required to be sold by the reporting person to cover tax withholding obligations in connection with the vesting of restricted stock units. These sales were automatic and intended to qualify under Rule 10b5-1.
- 98% of the restricted stock units vested on December 1, 2022, and the remaining 2% will vest on December 1, 2023.
- 73% of these restricted stock units vested on December 1, 2022, 25% will vest on December 1, 2023 and the remaining 2% will vest on December 1, 2024.
- 48% of these restricted stock units vested on December 1, 2022, 25% will vest on December 1, 2023, another 25% will vest on December 1, 2024 and the remaining 2% will vest on December 1, 2025.
Billionaire Hedge Funds
